Caudal epidural steroid injection as a novel therapy for treatment-induced neuropathy of diabetes in children: report of two cases.

Anju Bala, Babita Ghai, Arun George, Sayan Banerjee, Mohit Kumar, Devi Dayal
{"title":"Caudal epidural steroid injection as a novel therapy for treatment-induced neuropathy of diabetes in children: report of two cases.","authors":"Anju Bala, Babita Ghai, Arun George, Sayan Banerjee, Mohit Kumar, Devi Dayal","doi":"10.1515/jpem-2025-0005","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Treatment-induced neuropathy of diabetes (TIND) is a rare complication of rapid glycemic improvement, characterized by severe shooting pain, predominantly in the lower extremities. This report aims to highlight the clinical presentation of TIND and evaluate the effectiveness of caudal epidural steroid injections (CESI) in managing refractory pain in pediatric cases.</p><p><strong>Case presentation: </strong>We describe two pediatric cases of TIND following rapid improvement in glycemic control for type 1 diabetes. Both patients presented with debilitating pain and sleep disturbances that severely impacted their daily activities. Initial management with a combination of analgesics, pregabalin, gabapentin, and duloxetine failed to provide adequate relief. Subsequently, both patients received CESI with bupivacaine and methylprednisolone. Significant symptomatic improvement in pain and sleep was observed within 4-6 weeks post-intervention. At the 6-month follow-up, the pain relief was sustained, and no adverse effects were reported.</p><p><strong>Conclusions: </strong>These cases underscore the importance of recognizing TIND as a potential complication of rapid glycemic control and the challenges in its management. CESI appears to be a promising therapeutic option for children with refractory TIND, offering durable pain relief and improved quality of life. Further studies are needed to validate its efficacy and safety in larger cohorts.</p>","PeriodicalId":520684,"journal":{"name":"Journal of pediatric endocrinology & metabolism : JPEM","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pediatric endocrinology & metabolism : JPEM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jpem-2025-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Treatment-induced neuropathy of diabetes (TIND) is a rare complication of rapid glycemic improvement, characterized by severe shooting pain, predominantly in the lower extremities. This report aims to highlight the clinical presentation of TIND and evaluate the effectiveness of caudal epidural steroid injections (CESI) in managing refractory pain in pediatric cases.

Case presentation: We describe two pediatric cases of TIND following rapid improvement in glycemic control for type 1 diabetes. Both patients presented with debilitating pain and sleep disturbances that severely impacted their daily activities. Initial management with a combination of analgesics, pregabalin, gabapentin, and duloxetine failed to provide adequate relief. Subsequently, both patients received CESI with bupivacaine and methylprednisolone. Significant symptomatic improvement in pain and sleep was observed within 4-6 weeks post-intervention. At the 6-month follow-up, the pain relief was sustained, and no adverse effects were reported.

Conclusions: These cases underscore the importance of recognizing TIND as a potential complication of rapid glycemic control and the challenges in its management. CESI appears to be a promising therapeutic option for children with refractory TIND, offering durable pain relief and improved quality of life. Further studies are needed to validate its efficacy and safety in larger cohorts.

尾侧硬膜外类固醇注射作为治疗儿童糖尿病神经病变的新疗法:附2例报告。
目的:治疗性糖尿病神经病变(TIND)是一种罕见的血糖快速改善并发症,其特征是严重的射痛,主要发生在下肢。本报告旨在强调TIND的临床表现,并评估尾侧硬膜外类固醇注射(CESI)治疗小儿难治性疼痛的有效性。病例介绍:我们描述了2例儿童TIND病例后,血糖控制快速改善1型糖尿病。两名患者都表现出虚弱的疼痛和睡眠障碍,严重影响了他们的日常活动。最初使用镇痛药、普瑞巴林、加巴喷丁和度洛西汀联合治疗未能提供足够的缓解。随后,两名患者接受了布比卡因和甲基强的松龙的CESI。干预后4-6周,疼痛和睡眠症状明显改善。随访6个月,疼痛持续缓解,无不良反应报告。结论:这些病例强调了认识到TIND作为快速血糖控制的潜在并发症的重要性及其管理的挑战。CESI似乎是难治性TIND患儿的一种有希望的治疗选择,提供持久的疼痛缓解和改善生活质量。需要进一步的研究来验证其在更大人群中的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信